Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer.

@article{Rubagotti1996RiskON,
  title={Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer.},
  author={Alessandra Rubagotti and Anna Perrotta and Claudio Casella and Francesco M. Boccardo},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1996},
  volume={7 3},
  pages={
          239-44
        }
}
BACKGROUND Both chemotherapy and tamoxifen are widely used either alone or in combination as adjuvant treatment following mastectomy. Despite the fact that both of them exhibit carcinogenic properties in experimental models, detailed reports on the incidence of new primaries following chemotherapy and/or tamoxifen in patients with early breast cancer are limited. PURPOSE To investigate the incidence of new primaries (including opposite breast tumors and skin cancers) in untreated patients and… CONTINUE READING